<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03454841</url>
  </required_header>
  <id_info>
    <org_study_id>CMUMK202I</org_study_id>
    <nct_id>NCT03454841</nct_id>
  </id_info>
  <brief_title>Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor</brief_title>
  <acronym>DRAGON</acronym>
  <official_title>Comparison of Circadian Variability of Platelet Inhibition in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare circadian variability of antiplatelet effect of prasugrel
      and ticagrelor maintenance doses during the initial days after acute myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prasugrel and ticagrelor are two oral P2Y12 receptor antagonists recommended as a part of
      dual antiplatelet therapy with aspirin in patients with acute myocardial infarction. Both
      drugs exert comparable antiplatelet effect following a loading dose. However, pharmacodynamic
      differences exist between these P2Y12 receptor inhibitors. Prasugrel is a prodrug that
      requires hepatic activation and permanently binds to platelet P2Y12 receptors, whereas
      ticagrelor is an active drug and blocks P2Y12 receptors reversibly. Another important
      difference is that prasugrel maintenance dose is administered once daily, while ticagrelor
      requires next dosage every 12 hours. These fundamental distinctions may affect the degree of
      platelet inhibition on maintenance doses during the first days after acute myocardial
      infarction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circadian variability of platelet inhibition assessed with VASP</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Platelet inhibition evaluated with VASP assay at 8:00, 12:00, 16:00 and 20:00</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circadian variability of platelet inhibition assessed with Multiplate</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Platelet inhibition evaluated with Multiplate at 8:00, 12:00, 16:00 and 20:00</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity at 8:00 assessed with VASP</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with VASP assay at 8:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity at 12:00 assessed with VASP</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with VASP assay at 12:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity 16:00 assessed with VASP</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with VASP assay at 16:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity 20:00 assessed with VASP</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with VASP assay at 20:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity 08:00 assessed with Multiplate</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with Multiplate at 08:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity 12:00 assessed with Multiplate</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with Multiplate at 12:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity 16:00 assessed with Multiplate</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with Multiplate at 16:00</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High platelet reactivity 20:00 assessed with Multiplate</measure>
    <time_frame>Day 4 after acute myocardial infarction</time_frame>
    <description>Number of patients with high platelet reactivity evaluated with Multiplate at 20:00</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  provision of informed consent prior to any study specific procedures

          -  diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment
             elevation myocardial infarction

          -  male or non-pregnant female, aged 18-75 years old

          -  provision of informed consent for angiography and percutaneous coronary intervention

        Exclusion Criteria:

          -  treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before
             the study enrollment

          -  hypersensitivity to ticagrelor or prasugrel

          -  contraindications for ticagrelor or prasugrel

          -  current treatment with oral anticoagulant or chronic therapy with low-molecular-weight
             heparin

          -  active bleeding

          -  history of ischemic stroke or transient ischemic attack

          -  history of intracranial hemorrhage

          -  recent gastrointestinal bleeding (within 30 days)

          -  history of moderate or severe hepatic impairment

          -  history of major surgery or severe trauma (within 3 months)

          -  patient required dialysis

          -  manifest infection or inflammatory state

          -  concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole,
             voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir,
             nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin,
             carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment

          -  body weight below 60 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Kubica, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Adamski, MD, PhD</last_name>
    <phone>+48525854023</phone>
    <email>piotr.adamski@wp.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Wrocław Medical University</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnośląskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wiktor Kuliczkowski, MD, PhD</last_name>
      <phone>+48717842240</phone>
      <email>wkuliczkowski@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Wiktor Kuliczkowski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdalena Cielecka-Prynda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Dr. A. Jurasz University Hospital, Collegium Medicum, Nicolaus Copernicus University</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Adamski, MD, PhD</last_name>
      <phone>+48525854023</phone>
      <email>piotr.adamski@wp.eu</email>
    </contact>
    <investigator>
      <last_name>Aldona Kubica, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Adamski, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Małgorzata Ostrowska, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Prof. dr hab.</investigator_title>
  </responsible_party>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>VASP</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

